X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (25731) 25731
Newspaper Article (941) 941
Book Chapter (114) 114
Magazine Article (87) 87
Publication (55) 55
Dissertation (21) 21
Book Review (10) 10
Book / eBook (7) 7
Conference Proceeding (6) 6
Trade Publication Article (6) 6
Government Document (2) 2
Journal / eJournal (2) 2
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (16808) 16808
molecular-weight heparin (8151) 8151
molecular weight (7375) 7375
female (7366) 7366
male (6525) 6525
anticoagulants - therapeutic use (5182) 5182
heparin, low-molecular-weight - therapeutic use (4989) 4989
animals (4835) 4835
heparin (4603) 4603
hematology (4203) 4203
middle aged (4061) 4061
aged (3642) 3642
adult (3610) 3610
anticoagulants (3474) 3474
venous thromboembolism (3392) 3392
peripheral vascular disease (3376) 3376
thrombosis (3219) 3219
risk factors (3016) 3016
unfractionated heparin (2893) 2893
deep-vein thrombosis (2859) 2859
thromboembolism (2854) 2854
prevention (2826) 2826
surgery (2554) 2554
anticoagulants - administration & dosage (2481) 2481
anticoagulants - adverse effects (2324) 2324
heparin, low-molecular-weight - administration & dosage (2305) 2305
treatment outcome (2184) 2184
low molecular weight heparin (2117) 2117
heparin - therapeutic use (2032) 2032
enoxaparin (2027) 2027
pregnancy (1992) 1992
medicine, general & internal (1877) 1877
heparin, low-molecular-weight - adverse effects (1716) 1716
pharmacology & pharmacy (1692) 1692
prophylaxis (1643) 1643
fibrinolytic agents - therapeutic use (1566) 1566
low-molecular-weight heparin (1540) 1540
venous thrombosis (1516) 1516
heparin - pharmacology (1467) 1467
cardiac & cardiovascular systems (1463) 1463
cancer (1452) 1452
pulmonary-embolism (1447) 1447
venous thrombosis - prevention & control (1447) 1447
biochemistry & molecular biology (1439) 1439
aged, 80 and over (1407) 1407
thromboembolism - prevention & control (1406) 1406
risk (1374) 1374
rats (1371) 1371
pulmonary embolism (1347) 1347
heparin - adverse effects (1343) 1343
anticoagulation (1328) 1328
warfarin (1273) 1273
venous thromboembolism - prevention & control (1258) 1258
postoperative complications - prevention & control (1243) 1243
prospective studies (1215) 1215
venous thrombosis - drug therapy (1213) 1213
time factors (1208) 1208
therapy (1199) 1199
care and treatment (1193) 1193
retrospective studies (1188) 1188
heparin, low-molecular-weight - pharmacology (1178) 1178
analysis (1175) 1175
drug therapy (1144) 1144
heparin - administration & dosage (1123) 1123
thromboprophylaxis (1097) 1097
hemorrhage - chemically induced (1084) 1084
proteins (1081) 1081
anticoagulants - pharmacology (1078) 1078
research (1070) 1070
glycosaminoglycans (1046) 1046
dose-response relationship, drug (1009) 1009
mice (1004) 1004
management (983) 983
mortality (979) 979
health aspects (966) 966
oncology (934) 934
aspirin (921) 921
abridged index medicus (897) 897
risk-factors (894) 894
medicine & public health (886) 886
risk assessment (885) 885
kinetics (856) 856
thrombosis - prevention & control (852) 852
diagnosis (838) 838
venous thrombosis - etiology (838) 838
randomized controlled trials as topic (815) 815
complications (811) 811
adolescent (804) 804
blood coagulation - drug effects (802) 802
patients (800) 800
deep vein thrombosis (799) 799
pulmonary embolism - prevention & control (798) 798
thrombocytopenia - chemically induced (769) 769
incidence (755) 755
enoxaparin - therapeutic use (753) 753
low-molecular-weight (750) 750
deep venous thrombosis (747) 747
venous thromboembolism - etiology (722) 722
coagulation (712) 712
factor xa inhibitors (703) 703
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (24263) 24263
German (914) 914
French (726) 726
Spanish (319) 319
Russian (185) 185
Japanese (178) 178
Chinese (126) 126
Polish (94) 94
Italian (57) 57
Czech (54) 54
Portuguese (41) 41
Dutch (39) 39
Hungarian (35) 35
Turkish (35) 35
Danish (28) 28
Swedish (23) 23
Korean (18) 18
Norwegian (18) 18
Bulgarian (15) 15
Finnish (11) 11
Slovak (9) 9
Croatian (7) 7
Hebrew (7) 7
Slovenian (7) 7
Serbian (5) 5
Ukrainian (4) 4
Lithuanian (3) 3
Romanian (2) 2
Bosnian (1) 1
Icelandic (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 3, pp. 252 - 261
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 04/2017, Volume 2017, Issue 4, p. CD007557
Background Heparin‐induced thrombocytopenia (HIT) is an adverse drug reaction presenting as a prothrombotic disorder related to antibody... 
Thrombocytopenia | Anticoagulants | Heparin_induced thrombocytopenia (HIT) | Surgical Procedures, Operative | Medical prophylaxis | Medical treatment | Venous Thrombosis | Deep vein thrombosis | Heparin, Low‐Molecular‐Weight | Thrombosis | Randomized Controlled Trials as Topic | Pulmonary embolism | Prevention | Pulmonary Embolism (PE) | Blood disorders | Numbers Needed To Treat | Treatment | Deep vein thrombosis (DVT) related | Prevention: medical approaches | Heparin | Heart & circulation | Medicine General & Introductory Medical Sciences | Thromboembolism | Postoperative Complications | Thrombosis [etiology; prevention & control] | ED AMERICAN-COLLEGE | Thrombocytopenia [chemically induced, complications | RISK-FACTORS | Humans | Heparin [administration & dosage; adverse effects] | DEEP-VEIN THROMBOSIS | prevention & control | PATIENTS ANTITHROMBOTIC THERAPY | ANTIBODY-FORMATION | Postoperative Complications [chemically induced | Heparin, Low-Molecular-Weight [administration & dosage; adverse effects] | MEDICINE, GENERAL & INTERNAL | Anticoagulants [administration & dosage; adverse effects] | VENOUS THROMBOEMBOLISM | PORCINE HEPARIN | HIP-REPLACEMENT | HEMORRHAGIC COMPLICATIONS | CRITICALLY-ILL PATIENTS | Venous Thrombosis [etiology; prevention & control] | Anticoagulants - administration & dosage | Postoperative Complications - prevention & control | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Surgical Procedures, Operative - statistics & numerical data | Thrombocytopenia - chemically induced | Anticoagulants - adverse effects | Heparin - adverse effects | Thrombocytopenia - complications | Venous Thrombosis - etiology | Thrombosis - etiology | Thrombocytopenia - prevention & control | Venous Thrombosis - prevention & control | Heparin, Low-Molecular-Weight - administration & dosage | Thrombosis - prevention & control | Postoperative Complications - chemically induced
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 05/2008, Volume 99, Issue 5, pp. 807 - 818
Journal Article
Current Opinion in Pharmacology, ISSN 1471-4892, 2012, Volume 12, Issue 2, pp. 217 - 219
...Heparin is a complex polysaccharide-based anticoagulant drug that is essential for the practice of modern medicine [ 1 ]. Used in extracorporeal therapies... 
Internal Medicine | Medical Education | MOLECULAR-WEIGHT HEPARINS | ANTITHROMBIN-III | PHARMACOLOGY & PHARMACY | PENTASACCHARIDE | ENZYMATIC-SYNTHESIS | SULFATE | Anticoagulants - chemical synthesis | Bioengineering | Animals | Heparin - chemical synthesis | Humans | Heparin - biosynthesis
Journal Article
Analytical Biochemistry, ISSN 0003-2697, 06/2014, Volume 455, Issue 1, pp. 3 - 9
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2006, Volume 355, Issue 8, pp. 809 - 817
.... Heparin-induced thrombocytopenia is suspected. What diagnostic studies are warranted, and how should this patient be treated... 
ANTIBODIES | ARGATROBAN | MEDICINE, GENERAL & INTERNAL | RECOMBINANT HIRUDIN | RISK-FACTORS | THROMBOSIS | LEPIRUDIN | MOLECULAR-WEIGHT HEPARIN | HEMODIALYSIS-PATIENTS | PROSPECTIVE COHORT | ANTICOAGULATION | Thrombocytopenia | Case studies | Drug therapy | Mortality
Journal Article
Circulation (New York, N.Y.), ISSN 1524-4539, 2014, Volume 129, Issue 7, pp. 764 - 772
...-molecular-weight or unfractionated heparin for 5 to 11 days, we compared dabigatran 150 mg twice daily with warfarin... 
Antagonists & inhibitors | Recurrence | Thrombin | Warfarin | Hemorrhage | Venous thromboembolism | CARDIAC & CARDIOVASCULAR SYSTEMS | FONDAPARINUX | THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | RIVAROXABAN | INITIAL TREATMENT | PERIPHERAL VASCULAR DISEASE | ORAL ANTICOAGULANT-THERAPY | APIXABAN | UNFRACTIONATED HEPARIN | Anticoagulants - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Warfarin - adverse effects | Male | Antithrombins - administration & dosage | Dabigatran | Heparin - adverse effects | Warfarin - administration & dosage | Venous Thromboembolism - drug therapy | Young Adult | Benzimidazoles - administration & dosage | Adult | Female | Benzimidazoles - adverse effects | Venous Thromboembolism - epidemiology | beta-Alanine - analogs & derivatives | Acute Disease | beta-Alanine - adverse effects | Double-Blind Method | Hemorrhage - epidemiology | Risk Factors | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Antithrombins - adverse effects | Adolescent | Aged | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Usage | Care and treatment | Dabigatran etexilate | Thromboembolism | Anticoagulants | Benzimidazoles | Heparin, Low-Molecular-Weight | Life Sciences | Venous Thromboembolism | Antithrombins | Heparin | beta-Alanine
Journal Article
Journal Article